Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?

Journal Article (Journal Article;Review)

Glioblastoma (GBM) is fatal. The standard radiotherapy and chemotherapy (temozolomide) followed by an adjuvant phase of temozolomide provide patients with, on average, a 2.5 months benefit. New treatments that can improve sensitivity to the standard treatment are urgently needed. Herein, we review the mechanisms and utility of poly (ADP-ribose) polymerase inhibitors in combination with radiation therapy as a treatment option for GBM patients and the role of phosphatase and tensin homologue mutations as a biomarker of response.

Full Text

Duke Authors

Cited Authors

  • Lester, A; Rapkins, R; Nixdorf, S; Khasraw, M; McDonald, K

Published Date

  • March 2017

Published In

Volume / Issue

  • 19 / 3

Start / End Page

  • 273 - 278

PubMed ID

  • 27655368

Electronic International Standard Serial Number (EISSN)

  • 1699-3055

Digital Object Identifier (DOI)

  • 10.1007/s12094-016-1547-4


  • eng

Conference Location

  • Italy